All posts by: Michael Zand

About Michael Zand

A new mindset for the SDGs? Top takeaways from Singularity University’s Global Summit – Devex

Continue reading

2017-08-16 NEWS

Devex

A new mindset for the SDGs? Top takeaways from Singularity University’s Global Summit
Devex
Singularity University faculty explain how exponentially growing technologies — such as artificial intelligence, digital manufacturing and synthetic biology — will enable us to make dramatic gains in the years ahead. Through online courses and the

and more »

Continue reading

2017-08-16 NEWS

Monsanto adds another CRISPR platform to genetic toolbox
Farm and Dairy
ST. LOUIS — Monsanto Company has forged an agreement with ToolGen, Inc., a biotechnology company specializing in genome editing, to use ToolGen’s CRISPR technology platform to develop agricultural products. The companies announced Aug. 16 that …

Continue reading

2017-08-16 NEWS

Monsanto adds another CRISPR platform to genetic toolbox
Farm and Dairy
ST. LOUIS — Monsanto Company has forged an agreement with ToolGen, Inc., a biotechnology company specializing in genome editing, to use ToolGen’s CRISPR technology platform to develop agricultural products. The companies announced Aug. 16 that …

Continue reading

2017-08-16 NEWS

Monsanto adds another CRISPR platform to genetic toolbox
Farm and Dairy
ST. LOUIS — Monsanto Company has forged an agreement with ToolGen, Inc., a biotechnology company specializing in genome editing, to use ToolGen’s CRISPR technology platform to develop agricultural products. The companies announced Aug. 16 that …

and more »

Continue reading

2017-08-16 NEWS

NBC 5 Dallas-Fort Worth

Achromatopsia: Gene Therapy Cures Eye Disease?
NBC 5 Dallas-Fort Worth
Cataldo explained. “There are currently no approved and no effective treatments for achromatopsia,” said University of Florida surgical ophthalmologist Christine Kay. Kay is working to change that. She is one of a handful of experts testing a gene therapy.

Continue reading

2017-08-16 NEWS

Equities.com

uniQure (QURE): Gene Therapy Progress in Hemophilia B
Equities.com
uniQure (Nasdaq: QURE) is developing gene therapy treatments for hemophilia B (whose patients are deficient in, or have defective, clotting factor IX), Huntington’s disease and cardiovascular disease. Its platform uses adeno-associated virus (AAV